Living high and feeling low: Altitude, suicide, and depression

Harvard Review of Psychiatry

Volumn 26, Issue 2, 2018, Pages 43-56

  Kious, Brent M ^a   Kondo, Douglas G ^a,b   Renshaw, Perry F ^a,b,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

5 HTP; Altitude; Creatine; Depression; Hypoxia; Serotonin; Suicide; Tryptophan

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; CREATINE; SEROTONIN; TRYPTOPHAN; CREATININE;

ALTITUDE; ATMOSPHERIC PRESSURE; BRAIN BIOENERGETICS; BRAIN METABOLISM; DEMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; ENVIRONMENTAL FACTOR; HUMAN; HYPOBARISM; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTONIN METABOLISM; SOCIAL ASPECT; SUICIDAL IDEATION; SUICIDE; UNITED STATES; COMPLICATION; MAJOR DEPRESSION; METABOLISM; STATISTICS AND NUMERICAL DATA;

ALTITUDE; CREATININE; DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPOXIA; RESIDENCE CHARACTERISTICS; SUICIDE; TRYPTOPHAN; UNITED STATES;

EID: 85044233223     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000158     Document Type: Review

References (161)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593–602.
2. Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety 2010;27:78–89.
3. van der Voort TY, Seldenrijk A, van Meijel B, et al. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J Clin Psychiatry 2015;76: e809–14.
4. Markkula N, Harkanen T, Nieminen T, et al. Prognosis of depressive disorders in the general population: results from the longitudinal Finnish Health 2011 Study. J Affect Disord 2016;190:687–96.
5. Malone KM, Haas GL, Sweeney JA, Mann JJ. Major depression and the risk of attempted suicide. J Affect Disord 1995;34: 173–85.
6. Blair-West GW, Cantor CH, Mellsop GW, Eyeson-Annan ML. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord 1999;55:171–8.
7. Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression—a central role for the serotonin transporter? Pharmacol Ther 2015;147:1–11.
8. Weissman MM, Bland RC, Canino GJ, et al. Prevalence of suicide ideation and suicide attempts in nine countries. Psychol Med 1999;29:9–17.
9. Lopizzo N, Bocchio Chiavetto L, Cattane N, et al. Geneenvironment interaction in major depression: focus on experience-dependent biological systems. Front Psychiatry 2015;6:68.
10. Tempier R, Meadows GN, Vasiliadis H-M, et al. Mental disorders and mental health care in Canada and Australia: comparative epidemiological findings. Soc Psychiatry Psychiatr Epidemiol 2008;44:63–72.
11. Young SN. Elevated incidence of suicide in people living at altitude, smokers and patients with chronic obstructive pulmonary disease and asthma: possible role of hypoxia causing decreased serotonin synthesis. J Psychiatry Neurosci 2013;38: 423–6.
12. Katz IR. Is there a hypoxic affective syndrome? Psychosomatics 1982;23:846–53.
13. Cheng D, Yakobi R, Dobbins WN, Neuman K, Brenner B. Moderate altitude increases suicide deaths. Ann Emerg Med 2002;40:s55.
14. Cheng DC, Mendenhall TI, Brenner BE. Suicide rates strongly correlate with altitude. Acad Emerg Med 2005;12:141.
15. Brenner BE, Cheng D, Muller E, Clark S, Camargo CA. Suicide rates strongly correlate with altitude: a study of 3,060 US counties. Acad Emerg Med 2006;13:S195.
16. Haws CA, Gray DD, Yurgelun-Todd DA, Moskos M, Meyer LJ, Renshaw PF. The possible effect of altitude on regional variation in suicide rates. Med Hypotheses 2009;73: 587–90.
17. DelMastro K, Hellem T, Kim N, Kondo D, Sung YH, Renshaw PF. Incidence of major depressive episode correlates with elevation of substate region of residence. J Affect Disord 2011;129:376–9.
18. Brenner B, Cheng D, Clark S, Camargo CA Jr. Positive association between altitude and suicide in 2584 U.S. counties. High Alt Med Biol 2011;12:31–5.
19. Betz ME, Valley MA, Lowenstein SR, et al. Elevated suicide rates at high altitude: sociodemographic and health issues may be to blame. Suicide Life Threat Behav 2011;41: 562–73.
20. Kim N, Mickelson JB, Brenner BE, Haws CA, Yurgelun- Todd DA, Renshaw PF. Altitude, gun ownership, rural areas, and suicide. Am J Psychiatry 2011;168:49–54.
21. Selek S. Altitude, immigration and suicide rates: a study from Turkey. Psychiatry Investig 2013;10:89–91.
22. Huber RS, Coon H, Kim N, Renshaw PF, Kondo DG. Altitude is a risk factor for completed suicide in bipolar disorder. Med Hypotheses 2014;82:377–81.
23. Kim J, Choi N, Lee YJ, et al. High altitude remains associated with elevated suicide rates after adjusting for socioeconomic status: a study from South Korea. Psychiatry Investig 2014;11: 492–4.
24. Alameda-Palacios J, Ruiz-Ramos M, García-Robredo B. Suicide mortality in Andalusia, Spain: geographical distribution and relationship with antidepressants, altitude and socioeconomic inequalities. Rev Esp Salud Publica 2015;89: 283–93.
25. Mark TL, Shern DL, Bagalman JE, Cao Z. Ranking America’s mental health: an analysis of depression across the states. Alexandria, VA: Mental Health America, 2007.
26. National Survey on Drug Use and Health: comparison of 2012–2013 and 2013–2014 population percentages (50 states and the District of Columbia). http://www.samhsa.gov/data/sites/default/files/NSDUHsaeShortTermCHG2014/NSDUHsae ShortTermCHG2014.pdf
27. Carpenter A, Provorse C. The world almanac of the USA. New York: St. Martin’s, 1996.
28. Asiri SA. Suicidal ideation among patients with major depressive disorder living at high altitude. Med J Cairo Univ 2014;82: 223–8.
29. Huber RS, Kim TS, Kim N, et al. Association between altitude and regional variation of ADHDin youth. J Atten Disord 2015 Mar 25 [Epub ahead of print].
30. Fiedler KK, Kim N, Kondo DG, Renshaw PF. Cocaine use in the past year is associated with altitude of residence. J Addict Med 2012;6:166–71.
31. Kim T-S, Kondo DG, Kim N, Renshaw PF. Altitude may contribute to regional variation in methamphetamine use in the United States: a population database study. Psychiatry Investig 2014;11:430–6.
32. Ishikawa M, Yamanaka G, Yamamoto N, et al. Depression and altitude: cross-sectional community-based study among elderly high-altitude residents in the Himalayan regions. Cult Med Psychiatry 2016;40:1–11.
33. Jeong C, Ozga AT, Witonsky DB, et al. Long-term genetic stability and a high-altitude East Asian origin for the peoples of the high valleys of the Himalayan arc. Proc Natl Acad Sci U S A 2016;113:7485–90.
34. Xu S, Li S, Yang Y, et al. A genome-wide search for signals of high-altitude adaptation in Tibetans. Mol Biol Evol 2011;28: 1003–11.
35. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide inmood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646.
36. Bluml V, Regier MD, Hlavin G, et al. Lithium in the public water supply and suicidemortality in Texas. J Psychiatr Res 2013; 47:407–11.
37. Helbich M, Leitner M, Kapusta ND. Geospatial examination of lithium in drinking water and suicide mortality. Int J of Health Geogr 2012;11:19.
38. Huber RS, Kim N, Renshaw CE, Renshaw PF, Kondo DG. Relationship between altitude and lithium in groundwater in the United States of America: results of a 1992–2003 study. Geospat Health 2014;9:231–5.
39. Ishii N, Terao T, Araki Y, et al. Low risk of male suicide and lithium in drinking water. J Clin Psychiatry 2015;76:319–26.
40. Helbich M, Bluml V, Leitner M, Kapusta ND. Does altitude moderate the impact of lithium on suicide? A spatial analysis of Austria. Geospat Health 2013;7:209–18.
41. Rahn H, Otis AB. Man’s respiratory response during and after acclimatization to high altitude. Am J Physiol 1949;157:445–62.
42. Peacock AJ. Oxygen at high altitude. BMJ 1998;317:1063–6.
43. Lilienthal J, Riley R, Proemmel D, Franke R. An experimental analysis in man of the oxygen pressure gradient from alveolar air to arterial blood during rest and exercise at sea level and at altitude. Am J Physiol 1946;147:199–216.
44. Grocott MPW, Martin DS, Levett DZH, McMorrow R, Windsor J, Montgomery HE. Arterial blood gases and oxygen content in climbers on Mount Everest. N Engl J Med 2009; 360:140–9.
45. United States Board on Geographic Names. 2017. http://geonames.usgs.gov/.
46. Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001;345:107–14.
47. Arregui A. Es la depresión más frecuente en la altura: Resultados de un estudio piloto. Revista Medica Herediana 1995;6:182–6.
48. Gamboa JL, Caceda R, Arregui A. Is depression the link between suicide and high altitude? High Alt Med Biol 2011;12: 403–4.
49. Fagenholz PJ, Murray AF, Gutman JA, Findley JK, Harris NS. New-onset anxiety disorders at high altitude. Wilderness Environ Med 2007;18:312–6.
50. Bolmont B, Thullier F, Abraini JH. Relationships between mood states and performances in reaction time, psychomotor ability, and mental efficiency during a 31-day gradual decompression in a hypobaric chamber from sea level to 8848 m equivalent altitude. Physiol Behav 2000;71:469–76.
51. Abraini JH, Bouquet C, Joulia F, Nicolas M, Kriem B. Cognitive performance during a simulated climb of Mount Everest: implications for brain function and central adaptive processes under chronic hypoxic stress. Eur J Physiol 1998;436:553–9.
52. Nicolas M, Thullier-Lestienne F, Bouquet C, et al. An anxiety, personality, and altitude symptomatology study during a 31-day period of hypoxia in a hypobaric chamber experiment (Everest-COMEX 1997). J Environ Psychol 1999;19:407–14.
53. Nicolas M, Thullier-Lestienne F, Bouquet C, et al. A study of mood changes and personality during a 31-day period of chronic hypoxia in a hypobaric chamber (Everest-Comex 97). Psychol Rep 2000;86:119–26.
54. Bardwell WA, Ensign WY, Mills PJ. Mood disturbances endure after completion of high-altitudemilitary training. Fort Belvoir, VA: Defense Technical Information Center, 2003.
55. Bogdanova OV, Abdullah O, Kanekar S, Bogdanov VB, Prescot AP, Renshaw PF. Neurochemical alterations in frontal cortex of the rat after one week of hypobaric hypoxia. Behav Brain Res 2014;263:203–9.
56. Kanekar S, Bogdanova OV, Olson PR, Sung YH, D’Anci KE, Renshaw PF. Hypobaric hypoxia induces depression-like behavior in female Sprague‐Dawley rats, but not in males. High Alt Med Biol 2015;16:52–60.
57. Grover RF, Weil JV, Reeves JT. Cardiovascular adaptation to exercise at high altitude. Exerc Sport Sci Rev 1985;14:269–302.
58. Crapo RO, Jensen RL, Hegewald M, Tashkin DP. Arterial blood gas reference values for sea level and an altitude of 1,400 meters. Am J Respir Crit CareMed 1999;160:1525–31.
59. Leniger-Follert E, Lübbers DW, Wrabetz W. Regulation of local tissue PO2 of the brain cortex at different arterial O2 pressures. Pflugers Arch 1975;359:81–95.
60. Goodwin RD, Marusic A, Hoven CW. Suicide attempts in the United States: the role of physical illness. Soc Sci Med 2003;56: 1783–8.
61. Harwood DMJ, Hawton K, Hope T, Harriss L, Jacoby R. Life problems and physical illness as risk factors for suicide in older people: a descriptive and case‐control study. Psychol Med 2006;36:1265–74.
62. Goodwin RD, Demmer RT, Galea S, Lemeshow AR, Ortega AN, Beautrais A. Asthma and suicide behaviors: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Psychiatr Res 2012;46:1002–7.
63. Kuo C-J, Chen VC-H, Lee W-C, et al. Asthma and suicide mortality in young people: a 12-year follow-up study. Am J Psychiatry 2010;167:1092–9.
64. Goodwin RD, Lavoie KL, Lemeshow AR, Jenkins E, Brown ES, Fedoronko DA. Depression, anxiety, and COPD: the unexamined role of nicotine dependence. Nicotine Tob Res 2012;14: 176–83.
65. Webb RT, Kontopantelis E, Doran T, Qin P, Creed F, Kapur N. Suicide risk in primary care patients with major physical diseases: a case‐control study. Arch Gen Psychiatry 2012;69: 256–64.
66. Van den Bemt L, Schermer T, Bor H, et al. The risk for depression comorbidity in patients with COPD. Chest 2009;135: 108–14.
67. Jensen JA, Goodson WH, Hopf HW, Hunt TK. Cigarette smoking decreases tissue oxygen. Arch Surg 1991;126: 1131–4.
68. Aubin H-J, Berlin I, Reynaud M. Current smoking, hypoxia, and suicide. Am J Psychiatry 2011;168:326–7.
69. Luger TM, Suls J, Vander Weg MW. How robust is the association between smoking and depression in adults? A metaanalysis using linearmixed-effects models. Addict Behav 2014; 39:1418–29.
70. Chaiton MO, Cohen JE, O’Loughlin J, Rehm J. A systematic review of longitudinal studies on the association between depression and smoking in adolescents. BMC Public Health 2009;9:356.
71. Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend 2008;98:169–78.
72. Covey LS, Berlin I, Hu M-C, Hakes JK. Smoking and suicidal behaviours in a sample of US adults with low mood: a retrospective analysis of longitudinal data. BMJ 2012;2(3).
73. Pandey GN. Biological basis of suicide and suicidal behavior. Bipolar Disord 2013;15:524–41.
74. Kohler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: relevance for novel antidepressants. J Psychopharmacol 2016;30:13–22.
75. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996;29:2–11.
76. Owens MJ, Nemeroff CB. The serotonin transporter and depression. Depress Anxiety 1998;8 suppl 1:5–12.
77. Prioux-Guyonneau M, Cretet E, Jacquot C, Rapin JR, Cohen Y. The effect of various stimulated altitudes on the turnover of norepinephrine and dopamine in the central nervous system of rats. Eur J Physiol 1979;380:127–32.
78. Prioux-Guyonneau M, Mocaer-Cretet E, Redjimi-Hafsi F, Jacquot C. Changes in brain 5-hydroxytryptaminemetabolism induced by hypobaric hypoxia. Gen Pharmacol 1982;13: 251–4.
79. Ray K, Dutta A, Panjwani U, Thakur L, Anand JP, Kumar S. Hypobaric hypoxia modulates brain biogenic amines and disturbs sleep architecture. Neurochem Int 2011;58:112–8.
80. Davis JN, Carlsson A. The effect of hypoxia on monoamine synthesis, levels, and metabolism in the rat brain. J Neurochem 1973;21:783–90.
81. Benwell ME, Balfour DJ, Anderson JM. Smoking-associated changes in the serotonergic systems of discrete regions of human brain. Psychopharmacology 1990;102:68–72.
82. Ribeiro EB, Bettiker RL, Bogdanov M, Wurtman RJ. Effects of systemic nicotine on serotonin release in rat brain. Brain Res 1993;621:311–8.
83. Malone KM, Waternaux C, Haas GL, Cooper TB, Li S, Mann JJ. Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am J Psychiatry 2003;160:773–9.
84. Radha TG, Venkitasubramanian TA, Viswanathan R. Effect of acute hypoxia on blood serotonin in human beings and rats. Respiration 1976;33:64–9.
85. Kumar GK. Hypoxia and neurotransmitter synthesis. Am J Physiol Cell Physiol 2011;300:C743–51.
86. Boadle-Biber MC. Regulation of serotonin synthesis. Prog Biophys Mol Biol 1993;60:1–15.
87. Hasegawa H, Nakamura K. Tryptophan hydroxylase and serotonin synthesis regulation. In: Christian PM, Barry LJ, eds. Handbook of behavioral neuroscience. Amsterdam: Elsevier, 2010:183–202.
88. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003;299:76.
89. Katz IR. Oxygen affinity of tyrosine and tryptophan hydroxylases in synaptosomes. J Neurochem 1980;35:760–3.
90. Katz IR. Interaction between the oxygen and tryptophan dependence of synaptosomal tryptophan hydroxylase. J Neurochem 1981;37:447–51.
91. Poncet L, Denoroy L, Dalmaz Y, Pequignot JM. Activity of tryptophan hydroxylase and content of indolamines in discrete brain regions after a long-term hypoxic exposure in the rat. Brain Res 1997;765:122–8.
92. Nishikawa M, Kumakura Y, Young SN, et al. Increasing blood oxygen increases an index of 5-HT synthesis in human brain as measured using alpha-[(11)C]methyl-L-tryptophan and positron emission tomography. Neurochem Int 2005;47: 556–64.
93. Lin HC, Erickson SR, Balkrishnan R. Physician prescribing patterns of innovative antidepressants in the United States: the case of MDD patients 1993–2007. Int J Psychiatry Med 2011;42:353–68.
94. Bauer M, Monz BU, Montejo AL, et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 2008;23:66–73.
95. Fuller RW, Wong DT. Inhibition of serotonin reuptake. Fed Proc 1977;36:2154–8.
96. Osipova DV, Kulikov AV, Popova NK. C1473G polymorphism in mouse tph2 gene is linked to tryptophan hydroxylase-2 activity in the brain, intermale aggression, and depressive-like behavior in the forced swim test. J Neurosci Res 2009;87: 1168–74.
97. Kulikov AV, Tikhonova MA, Osipova DV, Kulikov VA, Popova NK. Association between tryptophan hydroxylase-2 genotype and the antidepressant effect of citalopram and paroxetine on immobility time in the forced swim test in mice. Pharmacol Biochem Behav 2011;99:683–7.
98. Siesser WB, Sachs BD, Ramsey AJ, et al. Chronic SSRI treatment exacerbates serotonin deficiency in humanized tph2 mutant mice. ACS Chem Neurosci 2013;4:84–8.
99. Sachs BD, Ni JR, Caron MG. Brain 5-HT deficiency increases stress vulnerability and impairs antidepressant responses following psychosocial stress. Proc Natl Acad Sci U S A 2015; 112:2557–62.
100. Kanekar S, Bogdanova O, Olson P, et al. Antidepressant efficacy in a rodentmodel of hypoxia-related depression: do SSRIs lose efficacy at altitude? Neuropsychopharmacology 2015;40: S334.
101. Jacobson LH, Cryan JF. Feeling strained? Influence of genetic background on depression-related behavior in mice: a review. Behav Genet 2007;37:171–213.
102. Zhang X, Gainetdinov RR, Beaulieu JM, et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005;45:11–6.
103. Van Den Bogaert A, Sleegers K, De Zutter S, et al. Association of brain-specific tryptophan hydroxylase, TPH2, with unipolar and bipolar disorder in a Northern Swedish, isolated population. Arch Gen Psychiatry 2006;63:1103–10.
104. Harvey M, Gagne B, Labbe M, Barden N. Polymorphisms in the neuronal isoform of tryptophan hydroxylase 2 are associated with bipolar disorder in French Canadian pedigrees. Psychiatr Genet 2007;17:17–22.
105. Cichon S, Winge I, Mattheisen M, et al. Brain-specific tryptophan hydroxylase 2 (TPH2): a functional Pro206Ser substitution and variation in the 5’-region are associated with bipolar affective disorder. Hum Mol Genet 2008;17:87–97.
106. Roche S, McKeon P. Support for tryptophan hydroxylase-2 as a susceptibility gene for bipolar affective disorder. Psychiatr Genet 2009;19:142–6.
107. De Luca V, Hlousek D, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. The interaction between TPH2 promoter haplotypes and clinical-demographic risk factors in suicide victims with major psychoses. Genes Brain Behav 2006;5:107–10.
108. Yoon HK, Kim YK. TPH2 -703G/T SNP may have important effect on susceptibility to suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:403–9.
109. Tsai SJ, Hong CJ, Liou YJ, et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:637–41.
110. Lim SW, Won HH, Kim H, et al. Genetic prediction of antidepressant drug response and nonresponse in Korean patients. PloS One 2014;9:e107098.
111. Sarris J, Murphy J, Mischoulon D, et al. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry 2016;173:575–87.
112. Shaw KA, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002;(1):CD003198.
113. Green AR, Aronson JK, Curzon G, Woods HF. Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol 1980;10:603–10.
114. Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia‐myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323:357–65.
115. Birdsall TC. 5-hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 1998; 3:271–80.
116. Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther 2006;109:325–38.
117. Jacobsen JP, Rudder ML, Roberts W, et al. SSRI augmentation by 5-hydroxytryptophan slow release: mouse pharmacodynamic proof of concept. Neuropsychopharmacology 2016;41: 2324–34.
118. Rahman MK, Toshiharu N, Takeshi K. Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with L-DOPA and L-5-hydroxytryptophan as substrates. Biochem Pharmacol 1981;30:645–9.
119. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects of creatine in the central nervous system. Brain Res Bull 2008;76:329–43.
120. Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, Fava M, Renshaw PF. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry 2008;63:1127–34.
121. Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry 1997;154:116–8.
122. Volz HP, Rzanny R, Riehemann S, et al. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci 1998;248: 289–95.
123. Renshaw PF, Parow AM, Hirashima F, et al. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry 2001;158:2048–55.
124. Shi XF, Kondo DG, Sung YH, et al. Frontal lobe bioenergetic metabolism in depressed adolescents with bipolar disorder: a phosphorus-31 magnetic resonance spectroscopy study. Bipolar Disord 2012;14:607–17.
125. Caverzasi E, Pichiecchio A, Poloni GU, et al. Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature. Funct Neurol 2012;27:13–22.
126. Ende G, Demirakca T, Tost H. The biochemistry of dysfunctional emotions: proton MR spectroscopic findings in major depressive disorder. Prog Brain Res 2006;156: 481–501.
127. Jia Y, Zhong S, Wang Y, Liu T, Liao X, Huang L. The correlation between biochemical abnormalities in frontal white matter, hippocampus and serum thyroid hormone levels in first-episode patients with major depressive disorder. J Affect Disord 2015;180:162–9.
128. Wang Y, Jia Y, Xu G, Ling X, Liu S, Huang L. Frontal white matter biochemical abnormalities in first-episode, treatmentnaive patients with major depressive disorder: a proton magnetic resonance spectroscopy study. J Affect Disord 2012;136: 620–6.
129. Sozeri-Varma G, Kalkan-Oguzhanoglu N, Efe M, Kiroglu Y, Duman T. Neurochemical metabolites in prefrontal cortex in patients with mild/moderate levels in first-episode depression. Neuropsychiatr Dis Treat 2013;9:1053–9.
130. Tae WS, Kim SS, Lee KU, Nam EC, Koh SH. Progressive decrease of N-acetylaspartate to total creatine ratio in the pregenual anterior cingulate cortex in patients with major depressive disorder: longitudinal 1H-MR spectroscopy study. Acta Radiol 2014;55:594–603.
131. Chen CS, Chiang IC, Li CW, et al. Proton magnetic resonance spectroscopy of late-life major depressive disorder. Psychiatry Res 2009;172:210–4.
132. Zhong S, Wang Y, Zhao G, et al. Similarities of biochemical abnormalities between major depressive disorder and bipolar depression: a proton magnetic resonance spectroscopy study. J Affect Disord 2014;168:380–6.
133. Steingard RJ, Yurgelun-Todd DA, Hennen J, et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry 2000;48:1053–61.
134. Murray AJ. Energy metabolism and the high-altitude environment. Exp Physiol 2016;101:23–7.
135. Jameel MN, Hu Q, Zhang J. Myocytes oxygenation and high energy phosphate levels during hypoxia. PloS One 2014;9: e101317.
136. Holloway C, Cochlin L, Codreanu I, et al. Normobaric hypoxia impairs human cardiac energetics. FASEB J 2011;25:3130–5.
137. Holloway CJ, Montgomery HE, Murray AJ, et al. Cardiac response to hypobaric hypoxia: persistent changes in cardiac mass, function, and energy metabolism after a trek to Mount Everest Base Camp. FASEB J 2011;25:792–6.
138. Raman L, Tkac I, Ennis K, Georgieff MK, Gruetter R, Rao R. In vivo effect of chronic hypoxia on the neurochemical profile of the developing rat hippocampus. Dev BrainRes 2005;156:202–9.
139. Jain K, Prasad D, Singh SB, Kohli E. Hypobaric hypoxia imbalances mitochondrial dynamics in rat brain hippocampus. Neurol Res Int 2015;2015:742059.
140. Maiti P, Singh SB, Muthuraju S, Veleri S, Ilavazhagan G. Hypobaric hypoxia damages the hippocampal pyramidal neurons in the rat brain. Brain Res 2007;1175:1–9.
141. Murray AJ, Horscroft JA. Mitochondrial function at extreme high altitude. J Physiol 2016;594:1137–49.
142. Levett DZ, Vigano A, Capitanio D, et al. Changes in muscle proteomics in the course of the Caudwell Research Expedition to Mt. Everest. Proteomics 2015;15:160–71.
143. Mathur R, Cox IJ, Oatridge A, Shephard DT, Shaw RJ, Taylor- Robinson SD. Cerebral bioenergetics in stable chronic obstructive pulmonary disease. AmJ Respir Crit Care Med 1999;160: 1994–9.
144. Muthuraju S, Pati S. Effect of hypobaric hypoxia on cognitive functions and potential therapeutic agents. Malays J Med Sci 2014;21:41–5.
145. Renshaw PR, Ongur D, Huber R, Yurgelun-Todd D. Suicide and brain chemical changes with altitude. Paper presented at the Congress of the International Society for Affective Disorders, London, April 2012.
146. Gonul AS, Kitis O, Ozan E, et al. The effect of antidepressant treatment on N-acetyl aspartate levels of medial frontal cortex in drug-free depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:120–5.
147. Wang Y, Jia Y, Chen X, et al. Hippocampal N-acetylaspartate and morning cortisol levels in drug-naive, first-episode patients with major depressive disorder: effects of treatment. J Psychopharmacol 2012;26:1463–70.
148. Huang Y, Chen W, Li Y, Wu X, Shi X, Geng D. Effects of antidepressant treatment on N-acetyl aspartate and choline levels in the hippocampus and thalami of post-stroke depression patients: a study using (1)H magnetic resonance spectroscopy. Psychiatry Res 2010;182:48–52.
149. D’Anci KE, Allen PJ, Kanarek RB. A potential role for creatine in drug abuse? Mol Neurobiol 2011;44:136–41.
150. Allen PJ. Creatine metabolism and psychiatric disorders: does creatine supplementation have therapeutic value? Neurosci Biobehav Rev 2012;36:1442–62.
151. Allen PJ, D’Anci KE, Kanarek RB, Renshaw PF. Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependentmanner. Neuropsychopharmacology 2010; 35:534–46.
152. Ahn N, Leem YH, Kato M, Chang H. Effects of creatine monohydrate supplementation and exercise on depressionlike behaviors and raphe 5-HT neurons in mice. J Exerc Nutrition Biochem 2016;20:24–31.
153. Pazini FL, Cunha MP, Azevedo D, et al. Creatine prevents corticosterone-induced reduction in hippocampal proliferation and differentiation: possible implication for its antidepressant effect. Mol Neurobiol 2016 Oct 6 [Epub ahead of print].
154. Lyoo IK, Kong SW, Sung SM, et al. Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res 2003;123: 87–100.
155. Kondo DG, Sung YH, Hellem TL, et al. Open-label adjunctive creatine for female adolescents with SSRIresistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affect Disord 2011;135: 354–61.
156. Kondo DG, Forrest LN, Shi X, et al. Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression. Amino Acids 2016; 48:1941–54.
157. Lyoo IK, Yoon S, Kim TS, et al. A randomized, doubleblind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry 2012;169:937–45.
158. Yoon S, Kim JE, Hwang J, et al. Effects of creatine monohydrate augmentation on brain metabolic and network outcome measures in women with major depressive disorder. Biol Psychiatry 2016;80:439–47.
159. Hellem TL, Lundberg KJ, Renshaw PF. A review of treatment options for co-occurring methamphetamine use disorders and depression. J Addict Nurs 2015;26:14–23; quiz E1.
160. Hellem TL, Sung YH, Shi XF, et al. Creatine as a novel treatment for depression in females usingmethamphetamine: a pilot study. J Dual Diagn 2015;11:189–202.
161. Nemets B, Levine J. A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression. Int Clin Psychopharmacol 2013;28:127–33.